A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.

2022

2022 Mar 02

1432-198X

<p>Pediatric chronic kidney disease (CKD) is characterized by many co-morbidities, including impaired growth and development, CKD-mineral and bone disorder, anemia, dysregulated iron metabolism, and cardiovascular disease. In pediatric CKD cohorts, higher circulating concentrations of fibroblast growth factor 23 (FGF23) are associated with some of these adverse clinical outcomes, including CKD progression and left ventricular hypertrophy. It is hypothesized that lowering FGF23 levels will reduce the risk of these events and improve clinical outcomes. Reducing FGF23 levels in CKD may be accomplished by targeting two key stimuli of FGF23 production-dietary phosphate absorption and iron deficiency. Ferric citrate is approved for use as an enteral phosphate binder and iron replacement product in adults with CKD. Clinical trials in adult CKD cohorts have also demonstrated that ferric citrate decreases circulating FGF23 concentrations. This review outlines the possible deleterious effects of excess FGF23 in CKD, summarizes data from the adult CKD clinical trials of ferric citrate, and presents the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) study, a randomized, placebo-controlled trial to evaluate the effects of ferric citrate on FGF23 in pediatric patients with CKD stages 3-4 (ClinicalTrials.gov Identifier NCT04741646).</p>

10.1007/s00467-022-05492-7

Pediatr Nephrol

35237863

Association Between Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) and Cognition in Children: Chronic Kidney Disease in Children (CKiD) Study.

2020

398-406

2020 Jul-Aug

2590-0595

<p><strong>Rationale &amp; Objective: </strong>Chronic kidney disease (CKD) in children is associated with cognitive dysfunction that affects school performance and quality of life. The relationship between CKD-mineral and bone disorder and cognitive function in children is unknown.</p>

<p><strong>Study Design: </strong>Observational study.</p>

<p><strong>Participants: </strong>702 children enrolled in the Chronic Kidney Disease in Children (CKiD) Study.</p>

<p><strong>Predictors: </strong>Plasma fibroblast growth factor 23 (FGF-23), parathyroid hormone (PTH), calcium, phosphorus, 25 hydroxyvitamin D (25[OH]D), and 1,25 dihydroxyvitamin D (1,25[OH]D).</p>

<p><strong>Outcomes: </strong>Neurocognitive tests of intelligence, academic achievement, and executive functions.</p>

<p><strong>Analytical Approach: </strong>Linear regression models to analyze the cross-sectional associations between logFGF-23, 25(OH)D, 1,25(OH)D, PTH, calcium, and phosphorus scores and the cognitive test scores of interest after adjustment for demographics, blood pressure, proteinuria, and kidney function.</p>

<p><strong>Results: </strong>At baseline, median age was 12 (95% CI, 8.3, 15.2) years and estimated glomerular filtration rate was 54 (40.5, 67.8) mL/min/1.73&nbsp;m. In fully adjusted analyses, 25(OH)D, 1,25(OH)D, PTH, calcium, and phosphorus scores did not associate with cognitive test scores. In fully adjusted analyses, logFGF-23 was associated with abnormal test scores for attention regulation (&nbsp;&lt;&nbsp;0.05); specifically, Conners' Continuous Performance Test II Errors of Omission (β&nbsp;=&nbsp;2.3&nbsp;[1.0, 3.6]), Variability (β=1.4 [0.4,&nbsp;-2.4]), and Hit Reaction Time (β&nbsp;=&nbsp;1.3&nbsp;[0.2, 2.4]). Children in the highest FGF-23 tertile group had 7% and 9% greater cognitive risk for&nbsp;Hit Reaction Time and Errors of Omission compared with those in the lowest tertile, respectively. In fully adjusted analyses, higher FGF-23 tertile was associated with increased cognitive risk (&nbsp;&lt;&nbsp;0.05) for Errors of Omission (β&nbsp;=&nbsp;0.4&nbsp;[0.1,&nbsp;0.7]) and Hit Reaction Time (β&nbsp;=&nbsp;0.4&nbsp;[0.1, 0.7]).</p>

<p><strong>Limitations: </strong>The study does not assess the cumulative&nbsp;effects of FGF-23 excess on cognitive function over time. Within-population stratified analyses were not performed due to limited sample size.</p>

<p><strong>Conclusions: </strong>In children with CKD, higher plasma FGF-23 level is associated with lower performance in targeted tests of executive function, specifically attention regulation, independent of glomerular filtration rate.</p>

10.1016/j.xkme.2020.03.005

Kidney Med

32775979